Clinical Efficacy Comparison between Rosuvastatin and Atorvastatin on Acute Myocardial Infarction in Patients with Premature Coronary Heart Disease

Objective To observe and analyze the short-term efficacy of different statins on acute myocardial infarction in patients with premature coronary heart disease. Methods We selected 70 patients with acute myocardial infarction admitted into our hospital for treatment of premature coronary artery disease between January 2012 and June 2013. The patients were randomly divided into experimental group(n=35) and control group(n=35). The experimental group were treated with rosuvastatin, and the control group of patients were given atorvastatin. We observed the rate of overall efficiency within 6 months after treatment, and total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), hepersensitive C-reactive protein(hs-CRP), left ventricular ejction fraction(LVEF), and flow-mediated dilation(FMD) were also observed before and after treatment. Results The overall efficacy rate in the experimental group at 6 months was 94.3% and in the control group was 88.6% with no significant difference between each other(P 0.05). TG and FMD of patients in the experimental group at 6 months did not significantly change(P 0.05), while LVEF of the experimental group was significantly higher(P 0.05), and hs-CRP, TC, LDL-C, and HDL-C of the experimental group were significantly lower than the control group(P 0.05). Conclusion Short-term comprehensive efficacy of rosuvastatin for treatment of premature coronary artery disease in patients with acute myocardial infarction is superior to atorvastatin.